These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37469827)

  • 1. A Comparison of the Outcomes of Transarterial Chemoembolization and Transarterial Radioembolization in the Management of Neuroendocrine Liver Metastases in Adults: A Systematic Review.
    Victory Srinivasan N; Venugopal S
    Cureus; 2023 Jun; 15(6):e40592. PubMed ID: 37469827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes.
    Ngo L; Elnahla A; Attia AS; Hussein M; Toraih EA; Kandil E; Killackey M
    Ann Surg Oncol; 2021 Apr; 28(4):1950-1958. PubMed ID: 33393019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.
    Yang B; Liang J; Qu Z; Yang F; Liao Z; Gou H
    PLoS One; 2020; 15(2):e0227475. PubMed ID: 32074102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.
    Luo Y; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Zarghampour M; Khoshpouri P; Ameli S; Li Z; Hu D; Kamel IR
    Eur Radiol; 2019 Oct; 29(10):5160-5171. PubMed ID: 30877462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis.
    Mosconi C; Solaini L; Vara G; Brandi N; Cappelli A; Modestino F; Cucchetti A; Golfieri R
    Cardiovasc Intervent Radiol; 2021 May; 44(5):728-738. PubMed ID: 33709272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
    Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
    Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
    Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional Therapies for Colorectal Liver Metastases: Systematic Review and Clinical Practice Guideline.
    Karanicolas P; Beecroft JR; Cosby R; David E; Kalyvas M; Kennedy E; Sapisochin G; Wong R; Zbuk K;
    Clin Colorectal Cancer; 2021 Mar; 20(1):20-28. PubMed ID: 33257278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Duan R; Gong F; Wang Y; Huang C; Wu J; Hu L; Liu M; Qiu S; Lu L; Lin Y
    World J Surg Oncol; 2023 Mar; 21(1):120. PubMed ID: 37004052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
    PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
    Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival Outcome.
    Yu SCH; Hui JW; Li L; Cho CC; Hui EP; Chan SL; Yeo WM
    Cardiovasc Intervent Radiol; 2022 Feb; 45(2):172-181. PubMed ID: 34604920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Aarts BM; Muñoz FMG; Wildiers H; Dezentjé VO; Baetens TR; Schats W; Lopez-Yurda M; Dresen RC; Wit-van der Veen BJ; Deroose CM; Maleux G; Beets-Tan RGH; Klompenhouwer EG
    Cardiovasc Intervent Radiol; 2021 Dec; 44(12):1868-1882. PubMed ID: 34322751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - a systematic review and network meta-analysis of survival data.
    Chow R; Simone CB; Jairam MP; Swaminath A; Boldt G; Lock M
    Acta Oncol; 2022 Apr; 61(4):484-494. PubMed ID: 34846988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.